Healthcare Innovation: Where Biology Meets the Next Trillion

Robotic surgery used to be a novelty. Intuitive Surgical turned it into a standard of care, and that playbook—take a proven clinical workflow, rebuild it with hardware and software, then lock in recurring revenue through consumables—is now the template every serious healthcare innovation company is chasing. The theme covers 94 companies, from large-cap anchors like Thermo Fisher Scientific and Regeneron Pharmaceuticals down to clinical-stage biotechs running some of the most ambitious biology of the decade.

The common thread is compounding technical leverage. Data platforms accelerate trials. Precision diagnostics shrink the addressable patient pool but explode the price per treatment. And manufacturing breakthroughs—the kind Thermo Fisher supplies infrastructure for—mean a novel therapy can go from sequence to vial faster than ever before.

mRNA and Cell Therapy Are Reshaping the Drug Frontier

BioNTech proved that mRNA could move from obscure platform to mass-deployed product in under two years. Now the company is redirecting that engine toward oncology, with personalized cancer vaccines in mid-stage trials. That ambition runs parallel to the allogeneic cell therapy push at companies like Allogene Therapeutics, which is engineering off-the-shelf CAR-T cells designed to sidestep the cost and complexity of patient-specific manufacturing.

Immatics is attacking the same problem from the T-cell receptor angle, targeting solid tumors that have largely resisted CAR-T to date. These are high-variance bets—binary clinical readouts, long timelines—but the potential payoff is treatments that work where chemotherapy consistently fails.

On the neuroscience side, CervoMed is targeting neuroinflammation in dementia, a mechanism the field sidelined for years while chasing amyloid. The pivot toward inflammation-driven neurodegeneration is gaining credibility, and smaller specialists are positioned to capture it before larger pharma moves in.

Diagnostics and Data Infrastructure Are the Quiet Compounders

The loudest headlines go to novel therapies. The durable margin goes to the picks-and-shovels layer. Guardant Health is building the liquid biopsy market—blood-based cancer detection that catches recurrence and guides treatment without repeat tissue sampling. The category is still early, but reimbursement coverage is expanding and clinical validation is stacking up.

Veeva Systems operates further up the value chain, providing the cloud infrastructure that life sciences companies use to run trials, manage regulatory submissions, and handle commercial data. It is not a drug company, but nearly every drug company in this theme depends on its software. That positioning creates a toll-road dynamic: as the innovation layer expands, Veeva's addressable market expands with it.

ResMed represents a different flavor of compounding—connected devices generating continuous patient data that tighten clinical outcomes and reduce hospital readmissions in sleep and respiratory care. The data flywheel here is already mature, which is why the stock trades on cash flow rather than pipeline optionality.

Becton Dickinson anchors the medical device infrastructure side, supplying the diagnostics and drug delivery systems that underpin everything from hospital workflows to at-home monitoring. It lacks the growth optics of a biotech, but its role in the system is load-bearing.

The Risk Is Timing, Not Direction

The structural case for this theme is clean: aging populations, rising chronic disease burden, and a technological stack—AI, genomics, advanced manufacturing—that is genuinely improving the biology-to-bedside pipeline. The execution risk is timing. Clinical failures are binary. Reimbursement decisions from CMS can reclassify a market overnight. And rate sensitivity hits speculative biotech harder than almost any other sector.

The companies with the most durable positioning are those that sit at convergence points: diagnostics that feed therapy selection, platforms that serve multiple modalities, infrastructure that scales with the whole ecosystem. Explore the full ETF library for ways to access the theme with diversified exposure across the 94 companies in the graph.